Details

Autor(en) / Beteiligte

• Ciurea, Stefan O.
• Kongtim, Piyanuch
• Srour, Samer
• Chen, Julianne
• Soebbing, Doris
• Shpall, Elizabeth
• Rezvani, Katayoun
• Nakkula, Robin
• Thakkar, Aarohi
• Troy, Ella C.
• Cash, Alex A.
• Behbehani, Gregory
• Cao, Kai
• Schafer, Jolie
• Champlin, Richard E.
• Lee, Dean A.

Titel

Results of a phase I trial with Haploidentical mbIL‐21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML

Ist Teil von

• American journal of hematology, 2024-05, Vol.99 (5), p.890-899

Ort / Verlag

Hoboken, USA: John Wiley & Sons, Inc

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• Natural killer (NK)‐cells have potent anti‐tumor effects, yet it remains unclear if they are effective for patients with relapsed acute myeloid leukemia (AML). In a phase I clinical trial, we treated 12 patients (median age 60 years) with refractory AML (median 5 lines of prior therapy, median bone marrow blast count of 47%) with fludarabine/cytarabine followed by 6 infusions of NK‐cells expanded from haploidentical donors using K562 feeder cells expressing membrane‐bound IL21 and 4‐1BBL. Patients received 106–107/kg/dose. No toxicity or graft‐versus‐host disease (GVHD) was observed and MTD was not reached. Seven patients (58.3%) responded and achieved a complete remission (CR) with/without count recovery. Median time to best response was 48 days. Five responding patients proceeded to a haploidentical transplant from the same donor. After a median follow‐up of 52 months, 1‐year overall survival (OS) for the entire group was 41.7%, better for patients who responded with CR/CRi (57.14%), and for patients who responded and underwent transplantation (60%). Persistence and expansion of donor‐derived NK‐cells were identified in patients' blood, and serum IFNγ levels rose concurrently with NK cell infusions. A higher count‐functional inhibitory KIR was associated with higher likelihood of achieving CR/CRi. In conclusion, we observed a significant response to ex vivo expanded NK‐cell administration in refractory AML patients without adverse effects. Swimmer plot of patients treated on clinical trial and CF‐iKIR scores.